8:00 am Check In & Morning Refreshments

8:25 am Chair’s Opening Remarks

8:30 am Exploring the State of Play for Ophthalmic Drug Delivery to the Retina

  • Justin Creel Executive Director, Device Development, Genentech

Synopsis

  • Examining recent developments in retinal drug delivery devices
  • Uncovering innovation in suprachoroidal injection and subretinal delivery devices
  • Exploring multiple routes of subretinal administration

Advancing Retinal Therapy With Sustained Release Implants to Reduce Treatment Frequency

9:00 am Uncovering the Journey of Genentech’s Susvimo Port Delivery System’s from Challenges to FDA Reapproval

Synopsis

  • Delving into the process of the reapproval journal
  • Uncovering the required modifications to ensure safety
  • Exploring clinical data on the efficacy of Susvimo

9:30 am Speed Networking Break

Synopsis

A prime chance to make the most of the in-person networking with a niche community of ophthalmic delivery

professionals working in the space. This session is designed to maximize your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the summit

10:00 am Morning Break

Advancements in Large Volume Formulations & High Viscosity Injectable Drug Delivery

11:00 am Unlocking Drug Delivery Mechanics for Extended Release Implants

  • Thomas Shepard Senior Director - Implantable Drug Delivery Sciences, Alcon

Synopsis

  • Assessing the impact of formulation composition on drug release profiles
  • Relating matrix biodegradation and drug release
  • Developing into in vitro and in vivo performance correlation

11:30 am Focused Panel: Establishing Robust Clinical Trial Design to Overcome Past Failings

  • Tess Abunto Director - Therapeutic Area Medical, Clinical Development & Eye Care, Abbvie
  • Karen Chu Global Program Head, Vice President, Ophthalmology, Regeneron Pharmaceuticals

Synopsis

  • Patient-Centric Approaches: How can clinical trial design be optimized to minimize patient burden and improve adherence
  • Site-Specific Considerations: How can sites be better supported to ensure successful study execution?
  • Innovative Trial Design: Explore the latest advancements in clinical trial design, such as decentralized trials, virtual visits, and innovative data collection methods

12:00 pm Networking Lunch

Overcoming Inflammatory Responses to Maximize Therapeutic Effect

1:00 pm Exploring the Evolving Landscape of Regulatory Approvals for Combination Products

Synopsis

  • Landscape overview of current regulatory requirements
  • Device design solutions to address regulatory challenges
  • Future of ophthalmic drug delivery in clinical trials

1:30 pm Navigating the Safety Landscape of Novel Drug Delivery

  • Karen Chu Global Program Head, Vice President, Ophthalmology, Regeneron Pharmaceuticals

Synopsis

  • Evaluating acceptable safety goals for novel therapeutic deliveries
  • Addressing safety challenges associated with novel delivery technologies
  • Managing adverse events related to delivery technologies

2:00 pm Afternoon Break & Poster Session

Synopsis

Immerse yourself in an engaging and relaxed atmosphere that encourages meaningful conversations and relationship

building. You’ll also have the chance to explore a range of exciting poster presentations of the latest ophthalmic delivery strategies and showcase your own innovations.

Advancing Drug Formulations & Combinations to Achieve Sustained Release

3:00 pm Advancing Targeted, Compartmentalized & Long-Acting Depot Delivery: Synergistic Combination of Particulate Formulation & Suprachoroidal Route of Administration

  • Viral Kansara Vice President - Preclinical Development, Clearside Biomedical

Synopsis

  • Outlining the aqueous suspension depot formation of small molecule therapeutics capabilities
  • Exploring the potential of suprachoroidal delivery as targeted and compartmentalized delivery platform
  • Delving into preclinical and clinical assessment of suprachoroidal axitinib and triamcinolone acetonide

3:30 pm Enhancing Ocular Drug Delivery Through Combined Microparticles, Nanoparticles & Hydrogels

Synopsis

  • Extending drug release and improving localization in the intraocular space
  • Reducing burden and frequency of treatment

4:00 pm Chair’s Closing Remarks